Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Articles by Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5